• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.

作者信息

Sabatier Renaud, Lopez Marc, Guille Arnaud, Billon Emilien, Carbuccia Nadine, Garnier Séverine, Adelaide José, Extra Jean-Marc, Cappiello Maria-Antonietta, Charafe-Jauffret Emmanuelle, Pakradouni Jihane, Viens Patrice, Gonçalves Anthony, Chaffanet Max, Birnbaum Daniel, Bertucci François

机构信息

Aix-Marseille University, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, and Institut Paoli-Calmettes, Marseille, France.

Institut Paoli-Calmettes, Marseille, France.

出版信息

JCO Precis Oncol. 2019 Dec;3:1-8. doi: 10.1200/PO.18.00310.

DOI:10.1200/PO.18.00310
PMID:35100682
Abstract
摘要

相似文献

1
High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.一名具有HER2扩增且经过大量预处理的转移性三阴性乳腺癌患者对西妥昔单抗反应良好。
JCO Precis Oncol. 2019 Dec;3:1-8. doi: 10.1200/PO.18.00310.
2
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.抗表皮生长因子受体（EGFR）抗体西妥昔单抗与DNA交联剂顺铂在吉非替尼耐药的MDA-MB-468细胞中的生长及分子相互作用：三阴性/基底样乳腺癌治疗的新前景
Int J Oncol. 2008 Dec;33(6):1165-76.
3
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.在接受过大量治疗的转移性结直肠癌患者中对表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）进行双重抑制。
Oncology. 2017;93(3):191-196. doi: 10.1159/000475818. Epub 2017 May 23.
4
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.西妥昔单抗与紫杉烷联合用于“三阴性”乳腺癌患者的1/2期试验。
Breast. 2014 Aug;23(4):435-8. doi: 10.1016/j.breast.2014.03.003. Epub 2014 May 14.
5
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.达沙替尼与西妥昔单抗和顺铂在三阴性乳腺癌细胞中具有协同作用。
J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.
6
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.表皮生长因子受体靶向治疗对缺氧反应的差异影响：对三阴性转移性乳腺癌治疗敏感性的影响。
PLoS One. 2011;6(9):e25080. doi: 10.1371/journal.pone.0025080. Epub 2011 Sep 22.
7
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.西妥昔单抗 PET 描绘了达沙替尼治疗三阴性乳腺癌时表皮生长因子受体细胞分布的变化。
Breast Cancer Res. 2020 Apr 15;22(1):37. doi: 10.1186/s13058-020-01270-1.
8
Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.靶向三阴性乳腺癌的 EGFR 可增强紫杉醇和西妥昔单抗偶联纳米金刚石纳米复合材料的治疗效果。
Acta Biomater. 2019 Mar 1;86:395-405. doi: 10.1016/j.actbio.2019.01.025. Epub 2019 Jan 16.
9
Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.伊沙匹隆单药或联合西妥昔单抗作为晚期/转移性三阴性乳腺癌的一线治疗方案。
Clin Breast Cancer. 2015 Feb;15(1):8-15. doi: 10.1016/j.clbc.2014.07.007. Epub 2014 Aug 15.
10
Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.下调 miR-155-5p 通过诱导细胞凋亡和细胞焦亡增强西妥昔单抗对三阴性乳腺癌细胞的抗肿瘤作用。
Aging (Albany NY). 2021 Jan 5;13(1):228-240. doi: 10.18632/aging.103669.

引用本文的文献

1
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI.增殖性双潜能三阴性乳腺癌（DTP TNBC）细胞中表皮生长因子受体（EGFR）向Src家族酪氨酸激酶的转换产生了对EGFR酪氨酸激酶抑制剂（EGFR TKI）的超磷酸化依赖性脆弱性。
Cancer Cell Int. 2025 Feb 19;25(1):55. doi: 10.1186/s12935-025-03691-4.
2
Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways.通过靶向代谢改变和上皮-间质转化途径利用药物重新利用来对抗乳腺癌
ACS Pharmacol Transl Sci. 2024 Oct 31;7(12):3780-3794. doi: 10.1021/acsptsci.4c00545. eCollection 2024 Dec 13.
3
Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors.
表皮生长因子受体（EGFR）和磷脂酰肌醇-3-激酶（PI3K）双重抑制剂消除三阴性乳腺癌细胞的转移特性
Cancers (Basel). 2023 Aug 4;15(15):3973. doi: 10.3390/cancers15153973.
4
Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.三阴性乳腺癌患者血清中表皮生长因子受体（EGFR）的表达：该生物标志物的预后价值
Ecancermedicalscience. 2022 Jul 20;16:1431. doi: 10.3332/ecancer.2022.1431. eCollection 2022.
5
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.联合聚焦下一代测序分析指导实体瘤精准肿瘤学：来自机构分子肿瘤委员会的回顾性分析
Cancers (Basel). 2022 Sep 12;14(18):4430. doi: 10.3390/cancers14184430.
6
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.前瞻性高通量基因组分析晚期癌症：PERMED-01 临床试验结果。
Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9.